METHODS OF TREATING A SUBJECT SUFFERING FROM IRRITABLE BOWEL SYNDROME

• US 20090012113A1
• Filed: 09/19/2008
• Published: 01/08/2009
• Est. Priority Date: 08/11/1999
• Status: Active Grant

• Current Assignee: Cedars-Sinai Medical Center (Cedars Sinai Health System)
• Original Assignee: Cedars-Sinai Medical Center (Cedars Sinai Health System)
• Inventors: Lin, Henry C., Pimentel, Mark
• Granted Patent: US 7,718,608 B2
• Time in Patent Office: Days
• US Class Current: 514/293
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/164 of a carboxylic acid with an aminoalcohol, e.g. ceramides
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/4164 1,3-Diazoles
• CPC Class Codes: A61K 31/43 Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• CPC Class Codes: A61K 31/437 the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/4468 having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/5415 ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• CPC Class Codes: A61K 31/545 Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins, cefaclor, or cephalexine
• CPC Class Codes: A61K 31/575 substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• CPC Class Codes: A61K 31/606 having amino groups
• CPC Class Codes: A61K 31/65 Tetracyclines
• CPC Class Codes: A61K 31/7036 having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 31/7052 having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
• CPC Class Codes: A61K 38/02 Peptides of undefined number of amino acids; Derivatives thereof
• CPC Class Codes: A61K 38/14 Peptides containing saccharide radicals; Derivatives thereof , e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
• CPC Class Codes: A61P 1/00 : Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 : Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 37/00 : Drugs for immunological or allergic disorders
• CPC Class Codes: C12Q 1/00 : Measuring or testing processes involving enzymes, nucleic acids or microorganisms measuring or testing apparatus with condition measuring or sensing means, e.g. colony counters, C12M1/34; Compositions therefor; Processes of preparing such compositions
• CPC Class Codes: G01N 2800/065 : Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
• CPC Class Codes: G01N 33/56911 : Bacteria
• CPC Class Codes: H04L 67/125 : involving control of end-device applications over a network
• CPC Class Codes: H04L 69/08 : Protocols for interworking; Protocol conversion

Abstract

Disclosed are methods of treating a subject suffering from irritable bowel syndrome which involves administering rifaximin to the subject and reducing the symptoms of irritable bowel syndrome. Also disclosed are methods of improving the symptoms in a subject caused by irritable bowel syndrome.

Claims

1. A method of treating a subject suffering from irritable bowel syndrome, comprising administering rifaximin to the subject, wherein said administration reduces the symptoms of irritable bowel syndrome.

2. The method of claim 1, wherein the rifaximin is administered orally.

3. The method of claim 1, wherein the rifaximin is administered in a unitized amount.

4. The method of claim 1, wherein the rifaximin is dehydrated rifaximin.

5. The method of claim 1, wherein the rifaximin is lyophilized rifaximin.

6. The method of claim 1, wherein the administering reduces the symptoms of irritable bowel syndrome based on visual analog scores.

7. The method of claim 1, wherein the administering reduces extraintestinal symptoms of irritable bowel syndrome.

8. The method of claim 7, wherein the extraintestinal symptoms include joint pain and fatigue.

9. The method of claim 1, wherein the administering results in at least partial eradication of the small intestinal bacterial overgrowth.

10. The method of claim 1, wherein the administering results in complete eradication of the small intestinal bacterial overgrowth.

11. The method of claim 1, wherein the symptoms of irritable bowel syndrome are reduced.

12. The method of claim 1, wherein the administering comprises swallowing the rifaximin.

13. The method of claim 1, wherein the rifaximin is administered at room temperature.

14. The method of claim 1, wherein the rifaximin is administered at a refrigerated temperature.

15. The method of claim 1, further comprising administering an intestinal lavage or enema.

16. The method of claim 1, further comprising administering an anti-inflammatory cytokine or an antagonist thereof.

17. The method of claim 1, further comprising administering an agent that modifies afferent neural feedback or sensory perception.

18. A method of improving the symptoms of a subject suffering from irritable bowel syndrome, comprising administering rifaximin to the subject, wherein said administration improves the symptoms of irritable bowel syndrome.

19. The method of claim 18, wherein the rifaximin is administered orally.

20. The method of claim 18, wherein the rifaximin is administered in a unitized amount.

21. The method of claim 18, wherein the rifaximin is dehydrated rifaximin.

22. The method of claim 18, wherein the rifaximin is lyophilized rifaximin.

23. The method of claim 18, wherein the improvement of irritable bowel syndrome is based on visual analog scores.

24. The method of claim 18, wherein the improvement further comprises improvement of extraintestinal symptoms of irritable bowel syndrome.

25. The method of claim 24, wherein the extraintestinal symptoms include joint pain and fatigue.

26. The method of claim 18, wherein the administering results in at least partial eradication of the small intestinal bacterial overgrowth.

27. The method of claim 18, wherein the administering results in complete eradication of the small intestinal bacterial overgrowth.

28. The method of claim 18, wherein the irritable bowel syndrome is treated.

29. The method of claim 18, wherein the improvement in symptoms of irritable bowel syndrome is greater than 90%.

30. The method of claim 18, wherein the administration of rifaximin comprises swallowing the rifaximin.

31. The method of claim 18, wherein the rifaximin is administered at room temperature.

32. The method of claim 18, wherein the rifaximin is administered at a refrigerated temperature.

33. The method of claim 18, further comprising administering an intestinal lavage or enema.

34. The method of claim 18, further comprising administering an anti-inflammatory cytokine or an antagonist thereof.

35. The method of claim 18, further comprising administering an agent that modifies afferent neural feedback or sensory perception.

36. A method of treating a subject suffering from irritable bowel syndrome, comprising:

providing a therapeutic regime that includes an antimicrobial agent, wherein the antimicrobial agent comprises rifaximin; and

administering the therapeutic regime to the subject to improve symptoms related to irritable bowel syndrome.

37. The method of claim 36, wherein the therapeutic regime is administered orally.

38. The method of claim 36, wherein the therapeutic regime is administered in a unitized amount.

39. The method of claim 36, wherein the rifaximin is dehydrated rifaximin.

40. The method of claim 36, wherein the rifaximin is lyophilized rifaximin.

41. The method of claim 36, wherein the therapeutic regime improves symptoms of irritable bowel syndrome based on visual analog scores.

42. The method of claim 36, wherein the improvement of symptoms further comprises improvement of extraintestinal symptoms of irritable bowel syndrome.

43. The method of claim 42, wherein the extraintestinal symptoms include joint pain and fatigue.

44. The method of claim 36, wherein the administering results in at least partial eradication of the small intestinal bacterial overgrowth.

45. The method of claim 36, wherein the administering results in complete eradication of the small intestinal bacterial overgrowth.

46. The method of claim 36, wherein the irritable bowel syndrome is treated.

47. The method of claim 36, wherein the improvement of symptoms related to irritable bowel syndrome is greater than 90%.

48. The method of claim 36, wherein the administration of the therapeutic regime comprises swallowing the rifaximin.

49. The method of claim 36, wherein the therapeutic regime is administered at room temperature.

50. The method of claim 36, wherein the therapeutic regime is administered at a refrigerated temperature.

51. The method of claim 36, further comprising administering an intestinal lavage or enema.

52. The method of claim 36, further comprising administering an anti-inflammatory cytokine or an antagonist thereof.

53. The method of claim 36, further comprising administering an agent that modifies afferent neural feedback or sensory perception.